Drug intelligence / Profile preview

18F-PI-2620

Development stage: Phase 3
Lead developer: Lantheus
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-PI-2620 is a next-generation, fluorine 18-labeled positron emission tomography (PET) imaging agent developed for the in vivo detection of tau pathology, a hallmark of several neurodegenerative diseases. It binds with high affinity to aggregated tau protein and enables visualization and quantification of tau deposits in the brain. The compound is currently in Phase 3 clinical development for Alzheimer's disease and has received FDA Fast Track Designation for use in Alzheimer's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). It is also being investigated for other neurodegenerative conditions such as Parkinson's disease and traumatic brain injuries. The drug was discovered through a collaboration between AC Immune and Life Molecular Imaging, with Life Molecular Imaging holding exclusive worldwide licensing rights[1][4][5][8].

Brand names: [18F]PI-2620
Other names: Tau-PET tracer - AC Immune

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on 18F-PI-2620.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-PI-2620.

Explore the full profile